Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Corvus Pharmaceuticals ( (CRVS) ) has issued an announcement.
On June 4, 2025, Corvus Pharmaceuticals announced interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The data showed that cohort 3, which received a higher dose, demonstrated earlier and deeper responses compared to cohorts 1 and 2, with significant improvements in Eczema Area and Severity Index (EASI) scores. The trial confirmed a favorable safety profile, and the company has initiated an extension cohort to explore longer treatment durations. This progress underscores soquelitinib’s potential as a safe and effective treatment option for atopic dermatitis, enhancing Corvus’s position in the biopharmaceutical industry.
The most recent analyst rating on (CRVS) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
Corvus Pharmaceuticals exhibits significant financial difficulties with no revenue and increasing losses. Technical indicators show a bearish trend, and valuation metrics are weak. However, clinical advancements and strategic governance changes provide some optimism. Overall, the stock is rated at the lower end of the scale due to its financial challenges and negative technical trends, with potential upside from clinical developments.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel approach to immunotherapy for cancer and immune diseases. Its lead product candidate, soquelitinib, is an oral small molecule drug targeting ITK, with other candidates in development for various cancer indications.
Average Trading Volume: 1,000,566
Technical Sentiment Signal: Buy
Current Market Cap: $310.8M
Find detailed analytics on CRVS stock on TipRanks’ Stock Analysis page.